Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 28, 2015 4:39 AM ET


Company Overview of Palatin Technologies Inc.

Company Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of various diseases in the United States. The company’s clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that is in Phase 3 clinical trials for the treatment of female sexual dysfunction (FSD). Its drug development programs include Melanocortin receptor-1 agonist peptides for the treatment of inflammatory and dermatologic disease indications; Melanocortin receptor-4 peptide agonists, which is in preclinical trials for the treatment of erectile dysfunction; PL-3994, a natriuretic peptide receptor-A agonist that is in Phase 2 clinical trials for the tre...

4B Cedar Brook Drive

Cranbury, NJ 08512

United States

Founded in 1986

18 Employees





Key Executives for Palatin Technologies Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 53
Total Annual Compensation: $462.5K
Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer and Secretary
Age: 58
Total Annual Compensation: $422.5K
Compensation as of Fiscal Year 2015.

Palatin Technologies Inc. Key Developments

Palatin Technologies Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2015

Palatin Technologies Inc. reported unaudited consolidated earnings results for the first quarter ended September 30, 2015. For the quarter, the company reported loss from operations of $11,797,651 compared to income from operations of $893,888 a year ago. Net loss was $12,409,919 or $0.08 per diluted share compared to net income of $794,674 or $0.01 per diluted share a year ago.

Palatin Technologies Inc. to Report Q1, 2016 Results on Nov 12, 2015

Palatin Technologies Inc. announced that they will report Q1, 2016 results at 9:00 AM, Eastern Standard Time on Nov 12, 2015

Palatin Technologies Inc., Q1 2016 Earnings Call, Nov 12, 2015

Palatin Technologies Inc., Q1 2016 Earnings Call, Nov 12, 2015

Similar Private Companies By Industry

Company Name Region
ImmunoNewco, Inc. United States
Velcura Therapeutics Inc. United States
Calypte Biomedical Corp. United States
Remedyne Corporation United States
Proteologics, Inc. United States

Recent Private Companies Transactions

Private Placement
July 2, 2015
Private Placement
December 23, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Palatin Technologies Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at